Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy
Jingjing Su, Yiting Fu, Zitong Cui, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 13

Showing 13 citing articles:

Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies
Nicolas Roussot, Courèche Kaderbhaï, François Ghiringhelli
Cancers (2025) Vol. 17, Iss. 5, pp. 906-906
Open Access | Times Cited: 1
Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions
Abdullah Younis, John G. Gribben
Immuno (2024) Vol. 4, Iss. 3, pp. 186-210
Open Access | Times Cited: 7
Management of metastatic melanoma with combinations including PD-1 inhibitors
Lara Valeska Maul, Egle Ramelyte, Reinhard Dummer, et al.
Expert Opinion on Biological Therapy (2025)
Closed Access
Immune checkpoint inhibitors: From friend to foe
Prem Rajak
Toxicology Reports (2025), pp. 102033-102033
Open Access
Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review
VEENA V. TOM, A. De la Fuente Hernández José, Sumit Mallick, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Multifaceted functions of tissue-resident memory T cells in tumorigenesis and cancer immunotherapy
Eun Suk Seo, Sung‐Kyu Lee, Young Min Son
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 6
Open Access
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 3
Insights for the immunotherapy in malignant melanoma: a new revolution
Jiangying Xuan, Zixu Gao, Chuanyuan Wei, et al.
Clinical Cancer Bulletin (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 1
Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis
Yongfeng Wang, Yanzong Zhao, Guangming Zhang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Construction of [89Zr]Zr-Labeled HuL13 for ImmunoPET Imaging of LAG-3 Checkpoint Expression on Tumor-Infiltrating T Cells
Lixin Ding, Feng Wang, Zilei Wang, et al.
Molecular Pharmaceutics (2024)
Closed Access
Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma
Anum Jalil, Melissa M Donate, Jane Mattei
Cancer Drug Resistance (2024)
Open Access
Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives
Alberto Savino, A. Rossi, S. Fagiuoli, et al.
Cancers (2024) Vol. 17, Iss. 1, pp. 76-76
Open Access
Molecular and modular intricacies of precision oncology
Ravneet Chhabra
Frontiers in Immunology (2024) Vol. 15
Open Access
Page 1

Scroll to top